• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Sarepta Therapeutics (NQ: SRPT )

    122.84 -2.16 (-1.73%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 14, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,000,461
    Open 124.09
    Bid (Size) 120.50 (1)
    Ask (Size) 123.00 (1)
    Prev. Close 125.00
    Today's Range 120.34 - 125.89
    52wk Range 55.25 - 146.68
    Shares Outstanding 93,148,652
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 9 Analysts
    Via Benzinga
    Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
    Sarepta is now just awaiting the FDA's decision on whether to fully approve its gene therapy, and for whom. 
    Via Investor's Business Daily
    Exposures Product Safety

    Performance

    YTD
    +27.68%
    +27.68%
    1 Month
    -7.46%
    -7.46%
    3 Month
    -0.91%
    -0.91%
    6 Month
    +30.78%
    +30.78%
    1 Year
    -5.83%
    -5.83%

    More News

    Read More
    Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate
    Via InvestorPlace
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    12 Analysts Have This To Say About Sarepta Therapeutics
    Via Benzinga
    What Analysts Are Saying About Sarepta Therapeutics Stock
    Via Benzinga
    Why Sarepta Therapeutics Stock Is Rising Today
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Sarepta Downgraded As FDA Decision Date Approaches, Shares Up 50% Over Last Six Months
    Via Benzinga
    Exposures Product Safety
    Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    The 2030 Millionaire’s Club: 3 Biotech Stocks to Buy Now
    Via InvestorPlace
    Jim Cramer: This Industrial Stock Is Doing 'Very Well'; Here's His Take On Palantir
    Via Benzinga
    Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again
    Via Investor's Business Daily
    3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
    Via InvestorPlace
    Exposures Product Safety
    Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Apple, Kellanova And 3 Stocks To Watch Heading Into Thursday
    Via Benzinga
    SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    1 Top Growth Stock to Buy and Hold for 10 Years
    Via The Motley Fool
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics Stock Shows Improved Technical Strength
    Via Investor's Business Daily
    Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst
    Via Investor's Business Daily
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.